Symbio Releases White Paper: “The Clinical State of Psoriasis”

Symbio has released their latest white paper “The Clinical State of Psoriasis” which aims to explain why biologics have become so popular and why their introduction has been so disruptive to classic topical drug studies.

Psoriasis is a common and often debilitating skin disease that affects millions of Americans each year. In the last few decades a variety of different pharmaceutical interventions have been brought to market with the intention of alleviating the suffering this ailment inflicts. These efforts have coalesced into two main classes of drugs: Topical medications and systemic treatments. These systemic, biologic treatments generally come from a newer class of drugs known as monoclonal antibodies, or MABs.

As the psoriasis market expands to include new systemic agents, clinical trials and their enrollment become increasingly complex. Due to the rise of treatment options such as biologics, topical psoriasis drugs have seen slow enrollment over the last decade


Success for Symbio at the 2022 AAD Annual Meeting

Symbio and Dow Development Laboratories exhibited at the 2022 AAD Annual Meeting from March 25 to March 29 at the Boston Convention & Exhibition Center in Boston, MA. The event was a huge success for all. It was wonderful to see so many familiar faces and to make new connections.

View videos of AAD Annual Meeting at the Symbio Booth and our 20th Anniversary Dinner Celebration at SPIN.





EADV Congress – A Successful Show in Madrid

Symbio and Dow Development Laboratories exhibited at the 28th EADV Congress, “The Modern Face of Dermatology” from October 9 to October 13, 2019 at IFEMA Congress Centre in Madrid, Spain.

The show was a great success as we were able to connect with our clients, friends and colleagues.


Founded in 1987, EADV is a non-profit association whose mission is to advance excellence in clinical care, research, education and training in the field of dermatology and venereology and to act as the advocate and educator of patients particularly those with cutaneous or venereal diseases.